Alternative oral exemestane formulation: Improved dissolution and permeation

International Journal of Pharmaceutics

Volumn 398, Issue 1-2, 2010, Pages 137-145

  Yavuz, Burçin ^a   Bilensoy, Erem ^a   Vural, Imran ^a   Şumnu, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anticancer drugs; Cyclodextrin; Exemestane; In vitro dissolution; In vitro permeation; Oral drug delivery

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; EXEMESTANE; HYDROXYPROPYL GAMMA CYCLODEXTRIN; METHYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SOLUBILITY; FREEZE DRYING; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; TABLET FORMULATION; X RAY ANALYSIS;

ADMINISTRATION, ORAL; ANDROSTADIENES; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; HUMANS; PERMEABILITY; SOLUBILITY; X-RAY DIFFRACTION;

EID: 77956217284     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.046     Document Type: Article

References (30)

1. Albers E., Müller B.W. Cyclodextrin derivatives in pharmaceuticals. CRC Crit. Rev. Ther. Drug Carrier Syst. 1995, 12:311-337.
2. Bilensoy E., Gürkaynak O., Ertan M., Şen M., Hincal A.A. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J. Pharm. Sci. 2008, 97:1519-1529.
3. Brewster M.E., Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug. Deliv. Rev. 2007, 59:645-666.
4. Challa R., Ahuja A., Ali J., Khar R.K. Cyclodextrins in drug delivery: an updated review. AAPS Pharm. Sci. Technol. 2005, 6:29-357.
5. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present, future. Nat. Rev. Drug Discov. 2004, 3:1023.
6. Duchéne D. Cyclodextrins and their industrial uses 1987, Editions de Santé, Paris.
7. FDA NDA 20753/S006 - Approved Labeling & Clinical Pharmacology and Biopharmaceutics Review(s).
8. Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4:117-212.
9. Johannessen D.C., Engan T., Di Salle E., Zurlo M.G., Paolini J., Ornati G., Piscitelli G., Kvinnsland S., Lonning P.E. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin. Cancer Res. 1997, 3:1101-1108.
10. Kirschner M.A. The role of hormones in the development of human breast cancer. Breast Cancer 3: Advances in Research and Treatment, Current Topics 1979, 199-226. Plenum Publishing Corp., New York. W.L. McGuire (Ed.).
11. Lambert D., O'Neill C.A., Padfield P.J. Methyl-β-cyclodextrin increases permeability of Caco-2 cell monolayers by displacing specific claudins from cholesterol rich domains associated with tight junctions. Cell. Physiol. Biochem. 2007, 20:495-506.
12. Liu L., Suyan Z. Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. J. Pharm. Biomed. Anal. 2006, 40:122-127.
13. Löbenberg R., Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000, 50:3-12.
14. Loftsson T. Cyclodextrins and the biopharmaceutical classification system of drugs. J. Incl. Phenom. Macrocycl. Chem. 2002, 44:63-67.
15. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins, I. drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
16. Lonning P.E. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res. Treat. 1998, 49:45.
17. Mauger J.W., Chilko D., Howard S. On the analysis of the dissolution data. Drug Dev. Ind. Pharm. 1986, 12:969-992.
18. Miller W.R., Dixon J.M. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002, 9:9-15.
19. Moore J.W., Flanner H.H. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Technol. 1996, 20:64-74.
20. Nakanishi K., Miyazaki S., Masada M., Miyajima K. Effects of cyclodextrins on biological membrane II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins. Chem. Pharm. Bull. 1992, 40:1252-1256.
21. Otagiri M., Uekama K., Ikeda K. Inclusion complexes of b-cyclodextrin with tranquilizing drugs phenothiazines in aqueous solution. Chem. Pharm. Bull. 1975, 23:188-195.
22. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 1996, 85:1142-1168.
23. Santen R.J., Santner S., Davis B., Veldhuis J., Samojilk E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab. 1978, 47:1257-1265.
24. Segaloff A. Hormones and mammary carcinogens. Advances in Research and Treatment, Experimental Biology 1978, 1-22. Plenum Publishing Corp., New York. W.L. McGuire (Ed.).
25. Theobald A.J. Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team. Int. J. Clin. Pract. 2000, 54:665-669.
26. Thompson D.O. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 1997, 14:1-104.
27. Valle M., Di Salle E., Jannuzzo M.G., Poggesi I., Rocchetti M., Spinelli R., Verotta D. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br. J. Clin. Pharmacol. 2005, 59:355-364.
28. Yavuz B., Bilensoy E., Şumnu M. Bioavailability file: exemestane. FABAD J. Pharm. Sci. 2007, 32:79-89.
29. Yavuz B., Bilensoy E., Şumnu M. Analytical method validation for HPLC assay of oral anticancer drug exemestane. FABAD J. Pharm. Sci. 2007, 32:15-22.
30. Zuo Z., Kwon G., Stevenson B., Diakur J., Wiebe L.I. Flutamide-hydroxy propyl-β-cyclodextrin complex: formulation, physical characterization, and absorption studies using the Caco-2 in vitro model. J. Pharm. Sci. 2000, 3:220-227.